Israeli Biotech Matricelf Targets U.S. Defense Sector for Spinal Cord Tech
Israeli biotech firm Matricelf presented its spinal cord repair technology at the U.S. Defense TechConnect conference, aiming to forge strategic partnerships with American defense and medical entities.
Spinal cord injuries present a severe medical challenge, particularly for military healthcare systems treating combat casualties. Israeli biotechnology company Matricelf, which develops technology for the regeneration of damaged neural tissue, is seeking to connect its innovation to the defense sector in the United States. As part of this strategic move, company representatives recently participated in the Defense TechConnect conference, an event that bridges technology companies with American government, defense, research, and medical stakeholders.
Expanding U.S. Defense and Medical Partnerships
Matricelf was represented at the conference by Prof. Alon Glazberg, former Chief Medical Officer of the IDF and currently a military medicine advisor to the company, and Dr. Tamar Harel, Vice President of Research and Development. According to company statements, the participation aimed to build long-term relationships with organizations engaged in developing and implementing medical technologies for trauma victims and wounded soldiers. The conference brings together officials from the U.S. Department of Defense, federal agencies, investors, and major research universities.
Innovative Neural Implants for Trauma Recovery
The technology developed by Matricelf is based on creating engineered, personalized neural implants using cells derived directly from the patient. The core development program focuses on traumatic spinal cord injuries, aiming to enable the regeneration of damaged neural tissue. This technology is currently under development, with the company positioning its activities as part of preparation for upcoming clinical trials.
"Matricelf is working to transition advanced scientific technology from the laboratory to the clinic," Harel stated, adding that connecting with leading research and medical institutions in the United States is a vital pillar in their development process and clinical preparation. Glazberg noted that the experience accumulated within Israeli military medicine highlights the urgent need for novel solutions to complex injuries, stating that the synergy between Israeli regenerative medicine innovation and global military medical systems can open unprecedented avenues for treating wounded personnel.
Strategic International Growth
For Matricelf, attending the conference forms part of a broader initiative to expand its international operations, with a primary focus on the United States. Dr. Alon Sinai, founder and president of Matricelf, emphasized that the goal extends beyond merely showcasing technology: building lasting partnerships with entities capable of advancing the innovation from research to clinical application and ultimately to patients remains the core objective.
